Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Rat, Human, Mouse|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||BALB/C mice were immunized with human epidermal keratin.|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:25-1:50|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA1-34220 detects Cytokeratin AE3 from human samples.
MA1-34220 has been successfully used in immunohistochemistry (paraffin tissue) applications.
The MA1-34220 immunogen is: BALB/C mice were immunized with human epidermal keratin.
This antibody detects basic (Type II) cytokeratins: Cytokeratin 1, Cytokeratin 2, Cytokeratin 3, Cytokeratin 4, Cytokeratin 5, Cytokeratin 6, Cytokeratin 7 and Cytokeratin 8.
This antibody recognizes all members of the basic subfamily: Cytokeratins 1, 2, 3, 4, 5, 6, and 8 (67, 65.5, 64, 59, 58, 52.5 kD).This antibody can be used to recognize normal and neoplastic cells of epithelial origin.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells.
MA1-34220 was used in immunohistochemistry to investigate the efficiency of a new method for the assessment of putative disseminating breast cancer stem cells
|Balic M,Rapp N,Stanzer S,Lin H,Strutz J,Szkandera J,Daidone MG,Samonigg H,Cote RJ,Dandachi N||Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry (19:33)||2011|
Coexistence of different tissue tumourigenesis in an N-methyl-N-nitrosourea-induced mammary carcinoma model: a histopathological report in Sprague-Dawley rats.
MA1-34220 was used in immunohistochemistry to investigate tumourigenesis in non-mammary tissues in the MNU-induced mammary tumour model
|Esendagli G,Yilmaz G,Canpinar H,Gunel-Ozcan A,Guc MO,Guc D||Laboratory animals (43:60)||2009|
BMP4 signaling regulates formation of Hertwig's epithelial root sheath during tooth root development.
MA1-34220 was used in immunohistochemistry to study the role of BMP4 signaling in regulating the formation of Hertwig's epithelial root sheath during tooth root development
|Hosoya A,Kim JY,Cho SW,Jung HS||Cell and tissue research (333:503)||2008|
Graft-versus-host-like disease complicating thymoma: lack of AIRE expression as a cause of non-hereditary autoimmunity?
MA1-34220 was used in immunohistochemistry to report on three cases of graft-versus-host-like enterocolonopathy
|Offerhaus GJ,Schipper ME,Lazenby AJ,Montgomery E,Morsink FH,Bende RJ,Musler AR,van Lier RA,van Noesel CJ||Immunology letters (114:31)||2007|
Mediastinal intraoperative radioisotope sentinel lymph node mapping in non-small-cell lung cancer.
MA1-34220 was used in immunohistochemistry to develop a method to map sentinel lymph nodes in non-small cell lung cancer patients
|Atinkaya C,Ozlem Küçük N,Koparal H,Aras G,Sak SD,Ozdemir N||Nuclear medicine communications (26:717)||2005|
Cytokeratin expression in lichen amyloidosus and macular amyloidosis.
MA1-34220 was used in immunohistochemistry to investigate the expression of cytokeratins in lichen and macular amyloidosis and their diagnostic value
|Apaydin R,Gürbüz Y,Bayramgürler D,Müezzinoglu B,Bilen N||Journal of the European Academy of Dermatology and Venereology : JEADV (18:305)||2004|
Assessment of the tumorigenesis and drug susceptibility of three new canine mammary tumor cell lines.
MA1-34220 was used in western blot to study the tumorigenesis and drug susceptibility of three new canine mammary tumor cell lines
|Chang CY,Chiou PP,Chen WJ,Li YH,Yiu JC,Cheng YH,Chen SD,Lin CT,Lai YS||Research in veterinary science (88:285)||2010|
58 kda cytokeratin; 65 kDa cytokeratin; 67 kDa cytokeratin; CK-1; CK-3; CK-5; CK-7; CK-72; cytokeratin 1; cytokeratin 3; cytokeratin 4; cytokeratin 6A; cytokeratin 6C; cytokeratin 6D; cytokeratin 7; cytokeratin-1; cytokeratin-2e; cytokeratin-3; cytokeratin-5; cytokeratin-6C; cytokeratin-6E; cytokeratin-7; cytokeratin-72; cytokeratin-8; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; epidermolytic hyperkeratosis 1; epithelial keratin-2e; hair alpha protein; K72; kamp-keratin derived antimicrobial peptide; KDAMP; keratin 1, type II; keratin 2, type II; keratin 3, type II; keratin 4, type II; keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types); keratin 5, type II; keratin 6, inner root sheath, 2; keratin 6A, , type II; keratin 6A, type II; keratin 7, type II; keratin 72, type II; keratin 8, type II; keratin K6h; keratin protein K6irs; keratin, 55K type II cytoskeletal; keratin, epidermal type II, K6A; keratin, simple epithelial type I, K7; keratin, type II cytoskeletal 6A; keratin-2 epidermis; keratin-2e; keratin-6C; keratin-7; keratin-72; sarcolectin; type II inner root sheath-specific keratin-K6irs2; type II mesothelial keratin K7; type-II keratin Kb1; type-II keratin Kb12; type-II keratin Kb2; type-II keratin Kb3; type-II keratin Kb35; type-II keratin Kb4; type-II keratin Kb5; type-II keratin Kb6; type-II keratin Kb7; type-II keratin Kb8
CARD2; CK-2e; CK-4; CK-6C; CK-6E; CK-8; CK1; CK3; CK4; CK5; CK6A; CK6C; CK6D; CK7; CK8; CYK4; CYK8; DDD; DDD1; EBS2; EHK; EHK1; EPPK; K1; K2C7; K2C8; K2e; K3; K4; K5; K6A; K6C; K6D; K6irs; K6IRS2; K7; K8; KB35; KO; KRT1; KRT1A; KRT2; KRT2A; KRT2E; KRT3; KRT5; KRT5A; KRT6; KRT6A; KRT6C; KRT6D; KRT6IRS2; KRT7; KRT72; KRT8; KRTA; KRTE; NEPPK; PC3; SCL; WSN1